Philip D Bonomi - JoVE Visualize

Showing results (21-30 of 30) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 30 results.

Cancers|April 3, 2021

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) TherapyNicole K Yun, Sherin J Rouhani, Christine M Bestvina, et al.

Journal of Applied Clinical Medical Physics|March 2, 2005

Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional studyRebecca Weinberg, Darryl G L Kaurin, Hak Choy, et al.

Journal of Cachexia, Sarcopenia and Muscle|April 23, 2024

Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysisPhilip D Bonomi, Jeffrey Crawford, Richard F Dunne, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.

Lung Cancer (Amsterdam, Netherlands)|February 19, 2017

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)Mark M Awad, Quincy S-C Chu, Leena Gandhi, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJohn V Heymach, Luis Paz-Ares, Filippo De Braud, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007

Novel agents in the treatment of lung cancer: Fourth Cambridge ConferenceThomas J Lynch, Philip D Bonomi, Charles Butts, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 13, 2016

Clinician Perspectives on Current Issues in Lung Cancer Drug DevelopmentSaiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2018

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical OutcomesNicolas Marcoux, Scott N Gettinger, Grainne O'Kane, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2012

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancerCharles M Rudin, Christine L Hann, Edward B Garon, et al.

Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 30 results.

Cancers|April 3, 2021

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) TherapyNicole K Yun, Sherin J Rouhani, Christine M Bestvina, et al.

Journal of Applied Clinical Medical Physics|March 2, 2005

Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional studyRebecca Weinberg, Darryl G L Kaurin, Hak Choy, et al.

Journal of Cachexia, Sarcopenia and Muscle|April 23, 2024

Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysisPhilip D Bonomi, Jeffrey Crawford, Richard F Dunne, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.

Lung Cancer (Amsterdam, Netherlands)|February 19, 2017

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)Mark M Awad, Quincy S-C Chu, Leena Gandhi, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJohn V Heymach, Luis Paz-Ares, Filippo De Braud, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007

Novel agents in the treatment of lung cancer: Fourth Cambridge ConferenceThomas J Lynch, Philip D Bonomi, Charles Butts, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 13, 2016

Clinician Perspectives on Current Issues in Lung Cancer Drug DevelopmentSaiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2018

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical OutcomesNicolas Marcoux, Scott N Gettinger, Grainne O'Kane, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2012

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancerCharles M Rudin, Christine L Hann, Edward B Garon, et al.

Pageof 3